When is the next results date for Bliss GVS Pharma?

No Upcoming Board Meetings

What does Bliss GVS Pharma do?

Bliss GVS Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, originally founded in 1984. As of March 2025, it reported net sales of ₹198 Cr and a net profit of ₹16 Cr, with a market cap of ₹1,436 Cr.

Overview:<BR>Bliss GVS Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1984 as Bliss Chemicals & Pharmaceuticals India Private Limited. It transitioned to a Public Limited Company and changed its name to Bliss Chemicals & Pharmaceuticals India Limited, later adopting the name Bliss GVS Pharma Limited on May 12, 2006. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 198 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 16 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 1,436 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.36%<BR>- Debt Equity: -0.12<BR>- Return on Equity: 8.03%<BR>- Price to Book: 1.40<BR><BR>Contact Details:<BR>Address: 102 Hyde Park Sakivihar Road, Andheri East Mumbai Maharashtra : 400072<BR>Tel: 91-22-42160000<BR>Email: info@blissgvs.com<BR>Website: http://www.blissgvs.com

What is the bonus history of the Bliss GVS Pharma?

Bliss GVS Pharma announced a bonus issue in a ratio of 3:5, with an ex-date of September 26, 2008, and a record date of September 30, 2008. Shareholders received 3 additional shares for every 5 shares held.

Bliss GVS Pharma has a recorded bonus history where they announced a bonus issue in a ratio of 3:5. The ex-date for this bonus was on September 26, 2008, and the record date was September 30, 2008. This means that for every 5 shares held, shareholders received 3 additional shares as a bonus. If you have any more questions about the company or its financial activities, feel free to ask!

Has Bliss GVS Pharma declared dividend?

Bliss GVS Pharma Ltd has declared a 50% dividend, amounting to 0.5 per share, with an ex-date of July 18, 2024. While recent performance shows a decline in the last 6 months, total returns over the past year and two years have been positive at 36.01% and 84.95%, respectively.

Bliss GVS Pharma Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 0.5<BR>- Ex-date: Jul-18-2024<BR><BR>Dividend Yield: 0.36%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.24%, with a dividend return of 0%, resulting in a total return of -13.24%.<BR><BR>Over the past year, the price return was 35.54%, the dividend return was 0.47%, leading to a total return of 36.01%.<BR><BR>In the last 2 years, the price return was 83.73%, with a dividend return of 1.22%, resulting in a total return of 84.95%.<BR><BR>For the 3-year period, the price return was 62.39%, the dividend return was 1.37%, culminating in a total return of 63.76%.<BR><BR>In the last 4 years, the price return was 21.5%, with a dividend return of 1.84%, leading to a total return of 23.34%.<BR><BR>Over the past 5 years, the price return was 41.11%, with a dividend return of 2.54%, resulting in a total return of 43.65%.<BR><BR>Overall, Bliss GVS Pharma has declared a dividend, contributing positively to total returns over longer periods, particularly in the 1-year and 2-year spans, while recent performance shows a decline in the short term.

Who are the peers of the Bliss GVS Pharma?

Bliss GVS Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Themis Medicare, Lincoln Pharma, Anuh Pharma, Wanbury, and Remus Pharma. While Bliss GVS Pharma has average management and below-average growth, its 1-year return of 33.37% is better than Themis Medicare's but lower than Wanbury's 104.73%.

Peers: The peers of Bliss GVS Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Themis Medicare, Lincoln Pharma., Anuh Pharma, Wanbury, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., Anuh Pharma, Wanbury, and Remus Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Divi's Lab., Torrent Pharma, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., and Wanbury, and Average growth is noted for Anuh Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Bliss GVS Pharma, Lincoln Pharma., and Anuh Pharma, while Good capital structure is found at Torrent Pharma and Themis Medicare, and Below Average at Wanbury.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wanbury at 104.73%, while Themis Medicare has the lowest at -33.90%. Bliss GVS Pharma's 1-year return of 33.37% is significantly higher than Themis Medicare's but lower than Wanbury's. Additionally, Themis Medicare, Lincoln Pharma., and Remus Pharma have negative six-month returns.

Who are in the management team of Bliss GVS Pharma?

As of March 2023, the management team of Bliss GVS Pharma includes Vibha G Sharma (Whole-time Director), Shruti Vishal Rao (Whole-time Director), Subramanian R Vaidya (Chairman & Independent Director), Santosh Parab (Non-Executive & Independent Director), Aditi Bhatt (Company Secretary & Compliance Officer), Shilpa Bhatia (Non-Executive & Independent Director), and Gagan Harsh Sharma (Managing Director). These members are responsible for the company's governance and operations.

As of March 2023, the management team of Bliss GVS Pharma includes the following members:<BR><BR>1. Vibha G Sharma - Whole-time Director<BR>2. Shruti Vishal Rao - Whole-time Director<BR>3. Subramanian R Vaidya - Chairman & Independent Director<BR>4. Santosh Parab - Non-Executive & Independent Director<BR>5. Aditi Bhatt - Company Secretary & Compliance Officer<BR>6. Shilpa Bhatia - Non-Executive & Independent Director<BR>7. Gagan Harsh Sharma - Managing Director<BR><BR>These individuals play key roles in the company's governance and operations.

Who are the top shareholders of the Bliss GVS Pharma?

The top shareholders of Bliss GVS Pharma include Narsimha Shibroor Kamath with 30.78%, Arian Investment Limited at 8.58%, and individual investors holding 32.63%. Additionally, 42 foreign institutional investors hold 13.18%, with no pledged promoter holdings.

The top shareholders of Bliss GVS Pharma include Narsimha Shibroor Kamath, who holds the highest promoter stake at 30.78%. The highest public shareholder is Arian Investment Limited, with a holding of 8.58%. Additionally, individual investors collectively hold 32.63% of the shares. The company also has 42 foreign institutional investors (FIIs) with a combined holding of 13.18%, while mutual funds hold a negligible amount through two schemes. Notably, there are no pledged promoter holdings.

How big is Bliss GVS Pharma?

As of 24th July, Bliss GVS Pharma Ltd has a market capitalization of 1,656.00 Cr, with recent net sales of 809.73 Cr and a net profit of 84.30 Cr. The company reported shareholder's funds of 1,050.38 Cr and total assets of 1,300.84 Cr.

As of 24th July, Bliss GVS Pharma Ltd has a market capitalization of 1,656.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Bliss GVS Pharma reported Net Sales of 809.73 Cr and a Net Profit of 84.30 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 1,050.38 Cr and Total Assets of 1,300.84 Cr.

How has been the historical performance of Bliss GVS Pharma?

Bliss GVS Pharma has experienced steady growth in net sales and profits, with net sales increasing from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025. However, rising expenditures and liabilities pose challenges despite improvements in profit before tax and consolidated net profit.

Answer:<BR>The historical performance of Bliss GVS Pharma shows a mixed trend in financial metrics over the years.<BR><BR>Breakdown:<BR>Bliss GVS Pharma's net sales have seen a steady increase from INR 747.45 crore in March 2022 to INR 809.73 crore in March 2025, reflecting a positive growth trajectory. The total operating income also rose correspondingly, reaching INR 809.73 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 619.62 crore in March 2024 to INR 683.04 crore in March 2025, impacting the operating profit, which decreased from INR 150.62 crore to INR 126.69 crore in the same period. Despite this, the profit before tax improved from INR 116.87 crore to INR 125.64 crore, leading to a profit after tax of INR 90.26 crore in March 2025, up from INR 81.58 crore in March 2024. The consolidated net profit also increased to INR 84.30 crore in March 2025 from INR 75.45 crore in March 2024. On the balance sheet, total assets grew from INR 1,211.59 crore in March 2024 to INR 1,300.84 crore in March 2025, while total liabilities also increased, but at a slower pace, from INR 1,211.59 crore to INR 1,300.84 crore. Cash flow from operating activities showed a slight increase to INR 105 crore in March 2025, compared to INR 102 crore in March 2024, indicating stable operational cash generation. Overall, while Bliss GVS Pharma has shown growth in sales and profits, the rising costs and liabilities present challenges that the company will need to address moving forward.

Are Bliss GVS Pharma latest results good or bad?

Bliss GVS Pharma's latest results show strong revenue growth with ₹244.40 crores in Q2 FY26, but profitability has declined sharply, with a net profit drop of 36.69% from the previous quarter. Investors should be cautious due to concerns about earnings quality, leading to a current stock rating of "Hold."

Bliss GVS Pharma's latest results present a mixed picture. On one hand, the company achieved record revenue of ₹244.40 crores in Q2 FY26, reflecting a strong sequential growth of 17.80% and a year-on-year increase of 12.27%. This indicates robust demand for its pharmaceutical products.<BR><BR>However, profitability has come under significant pressure. The net profit for the quarter was ₹27.25 crores, which represents a sharp decline of 36.69% compared to the previous quarter, although it is a 12.32% increase year-on-year. The operating margins also contracted dramatically, falling to 13.0% from 19.92% in the previous quarter, raising concerns about the sustainability of profit levels.<BR><BR>Additionally, a notable portion of the profit came from other income, which constituted nearly half of the profit before tax. This reliance on non-operating income raises questions about the quality of earnings and the core operational performance of the company.<BR><BR>Overall, while the revenue growth is commendable, the significant drop in profitability and the concerns regarding earnings quality suggest that investors should approach Bliss GVS Pharma with caution. The current rating for the stock is "Hold," indicating that while there are strengths, there are also significant risks that need to be monitored closely.

Should I buy, sell or hold Bliss GVS Pharma?

Is Bliss GVS Pharma overvalued or undervalued?

As of December 1, 2025, Bliss GVS Pharma's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 15.00 and an EV to EBITDA of 12.07, especially when compared to peers like Sun Pharma and Cipla, despite a year-to-date return of -5.53% relative to the Sensex's 9.60%.

As of 1 December 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company appears to be undervalued, with a PE ratio of 15.00, an EV to EBITDA of 12.07, and a PEG ratio of 0.85, all of which suggest that it is trading at a discount compared to its peers. <BR><BR>In comparison, Sun Pharma has a significantly higher PE ratio of 37.56 and an EV to EBITDA of 24.83, while Cipla, another peer, has a PE of 22.63 and an EV to EBITDA of 16.01. These comparisons reinforce the attractiveness of Bliss GVS Pharma's valuation. Despite recent underperformance relative to the Sensex, with a year-to-date return of -5.53% compared to the Sensex's 9.60%, the company's fundamentals suggest it is well-positioned for future growth.

Is Bliss GVS Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bullish, supported by bullish MACD readings and daily moving averages, but tempered by bearish Bollinger Bands and a mildly bearish KST, indicating a cautious outlook with underlying weakness.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the weekly and monthly MACD readings, which remain bullish. However, the weekly Bollinger Bands indicate a bearish sentiment, while the moving averages on the daily timeframe are bullish. The KST shows a mildly bearish trend on both weekly and monthly charts, and Dow Theory reflects a mildly bullish stance on the weekly timeframe but no trend on the monthly. Overall, the mixed signals suggest a cautious bullish outlook with some underlying weakness.

Why is Bliss GVS Pharma falling/rising?

As of 03-Dec, Bliss GVS Pharma Ltd's stock price is rising to 154.90 after a trend reversal, despite a negative performance over the past week and year-to-date. The recent increase is supported by attractive valuation metrics, though declining investor participation suggests caution.

As of 03-Dec, Bliss GVS Pharma Ltd's stock price is rising, currently at 154.90, reflecting a change of 0.55 (0.36%) upward. This increase comes after a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock has outperformed its sector by 0.37% today, indicating a positive shift in performance relative to its peers.<BR><BR>Despite a negative performance over the past week and year-to-date, where the stock has seen declines of 7.16% and 5.92% respectively, the recent uptick may be attributed to its attractive valuation metrics. The company has a low debt-to-equity ratio and a return on equity (ROE) of 9.7, suggesting financial stability. Furthermore, while the stock has generated a return of -5.29% over the past year, its profits have increased by 18.4%, and it has a price-to-earnings growth (PEG) ratio of 0.8, indicating that it may be undervalued compared to its historical averages.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 45.19% against the 5-day average, which could indicate caution among investors. The stock is currently trading above its 200-day moving average but below its shorter-term moving averages, suggesting mixed signals in terms of momentum.<BR><BR>Overall, the combination of a recent price increase, improved valuation metrics, and a trend reversal contributes to the current rise in Bliss GVS Pharma's stock price.

Which are the latest news on Bliss GVS Pharma?